ReviewLeukemia2025
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma.
Xavier Leleu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ReviewLeukemia2025
Xavier Leleu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.